替吉奥一线治疗晚期胃癌的研究进展

doi:10.3760/cma.j.issn.1673-422X.2014.03.016

摘要/Abstract

摘要： 晚期胃癌失去手术指征，化疗可延长患者的生存时间并提高生活质量，是主要治疗选择。但针对晚期胃癌目前仍无标准化疗方案。替吉奥自上市以来，在胃癌治疗中应用广泛，一些研究采用替吉奥与顺铂、紫杉类或伊立替康等细胞毒类药物联合一线治疗晚期胃癌，有效率在40%～50%，且安全性好。

关键词: 胃肿瘤, 药物疗法, 替吉奥

Abstract: Patients with advanced gastric cancer lose the surgical indications. Chemotherapy can improve the overall survival and quality of life, which is the main treatment option. But there is no standard chemotherapy regimen for the patients with advanced gastric cancer. Since its initial approval, S-1 is widely used in gastric cancer. Several studies were performed to explore combinations of S-1 with other cytotoxic drugs such as platinum, docetaxel, paclitaxel, and irinotecan. All these combinations were found to be promising, with response rates of around 40%-50% and relatively favorable safety profiles.

Key words: Stomach neoplasms, Drug therapy, S-1

姜凤娥, 孙萍. 替吉奥一线治疗晚期胃癌的研究进展[J]. 国际肿瘤学杂志, 2014, 41(3): 211-213.

JIANG Feng-E, SUN Ping. S-1 as first-line treatment for advanced gastric cancer[J]. Journal of International Oncology, 2014, 41(3): 211-213.

参考文献

［1］吴春晓，郑莹，鲍萍萍，等. 上海市胃癌发病流行现况与时间趋势分析［J］. 外科理论与实践, 2008, 13(1):2429. ［2］ Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S1 in metastatic gastric cancer: a randomised phase 3 study［J］. Lancet Oncol, 2009, 10(11):10631069. ［3］ Imamura H, Kishimoto T, Takiuchi H, et al. Phase II study of S1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404)［J］. J Chemother, 2013, 15(8):13361341. ［4］ Koizumi W, Narahara H, Hara T, et al. S1 plus cisplatin versus S1 alone for firstline treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial［J］. Lancet Oncol, 2008, 9(3):215221. ［5］ Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial［J］. J Clin Oncol, 2010, 28(9):15471553. ［6］ Ajani JA, Buyse M, Lichinitser M. Combination of cisplatin/S1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5fluorouracil in the FirstLine Advanced Gastric Cancer Study［J］. Eur J Cancer, 2013, 49(17):36163624. ［7］ Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S1 as firstline treatment for advanced gastric cancer (GSOX study)［J］. Ann Oncol, 2010, 21(5):10011005. ［8］ Yang L, Song Y, Zhou AP, et al. A phase Ⅱ trial of oxaliplatin plus S1 as a firstline chemotherapy for patients with advanced gastric cancer［J］. Chin Med J(Engl), 2013, 126(18): 34703474. ［9］ Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S1oxaliplatin versus capecitabineoxaliplatin in advanced gastric cancer［J］. Eur J Cancer, 2012, 48(4):518526. ［10］ Shuichi Hironaka, Kentaro Yamazaki, Keisei Taku, et al. Phase I Study of Docetaxel, Cisplatin and S1 in Patients with Advanced Gastric Cancer［J］. Jpn J Clin Oncol, 2010, 40(11):10141020. ［11］ Kunisaki C, Takahashi M, Makino H, et al. Phase Ⅱ study of biweekly docetaxel and S1 combination chemotherapy as firstline treatment for advanced gastric cancer［J］. Cancer Chemother Pharmacol, 2011, 67(6): 13631368. ［12］ Cui Y, Li Q, Yu Y, Chen Y, et al. Combination of lowdose docetaxel and standarddose S1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor［J］. Cancer Chemother Pharmacol, 2013, 71(1):145152. ［13］ Kunisaki C, Takahashi M, Ono HA, et al. Biweekly Docetaxel and S1 combination chemotherapy as firstline treatment for elderly patients with advanced gastric cancer［J］. Anticancer Res, 2013, 33(2):697704. ［14］ Narahara H, Ishii H, Imamura H, et al. Randomized phase Ⅲ study comparing the efficacy and safety of irinotecan plus S1 with S1 alone as firstline treatment for advanced gastric cancer (study GC0301/TOP002)［J］. Gastric Cancer, 2011, 14(1):7280. ［15］ Park SR, Kong SY, Rhee J, et al. Phase Ⅱ study of a triplet regimen of S1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results［J］. Ann Oncol， 2011, 22(4):890896.

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[4]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[5]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[6]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[7]	邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[8]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[9]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[12]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[13]	姬薇, 关泉林, 陈雅蕊, 焦福智, 罗倩文. 血脂水平与胃癌的相关性[J]. 国际肿瘤学杂志, 2023, 50(3): 183-185.
[14]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻. 胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[15]	杨俊, 李荣, 曾建昌. 复方苦参注射液联合SOX方案治疗老年晚期胃癌的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(2): 82-86.